2:36
Hodgkin lymphoma: difficulties faced in geriatrics
Wendy Osborne
1:54
Promising results for venetoclax across multiple hematological malignancies
Giovanni Martinelli
2:18
Novel drug combinations for Hodgkin lymphoma: more effective & less toxic
Anna Sureda
1:14
Checkmate 205 study results: nivolumab in classical Hodgkin Lymphoma
Graham Collins
1:11
Hodgkin lymphoma: when autologous transplant is unsuccessful
Stephen Robinson
4:15
Advanced Hodgkin lymphoma: AHL2011 data update from EHA 2018
Olivier Casasnovas
1:57
Biomarkers in lymphoma
Arjan Diepstra
3:31
Brentuximab vedotin plus ESHAP: complete remission in R/R Hodgkin lymphoma
Ramon Garcia-Sanz
2:22
Novel therapies in minimizing transplant complications
Mohamad Mohty
3:00
EBMT 2018: Updates on advanced Hodgkin lymphoma treatment
Martin Hutchings
1:31
ABVD vs. escBEACOPP in HL: a 10-year study
George Follows
1:13
Checkpoint inhibitor/bispecific antibody combo: REGN2810 and REGN1979 in B-lymphoid malignancies
Anthony Mato
3:09
ECHELON-1 trial data from ASH 2017: controversies and clinical translation
Graham Collins
2:30
New antibody-drug conjugates for lymphoma
Graham Collins
iwNHL 2017: T-cell lymphomas, Hodgkin’s lymphoma, immunotherapy and epigenetics
Francesco d'Amore et al.
1:47
Latest research in Hodgkin lymphoma
Anas Younes
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals